Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Articles|May 1, 2011
- Pharmaceutical Technology-05-01-2011
- Volume 2011 Supplement
- Issue 3
Pharmaceutical Technology North America, Bioprocessing Supplement 2011 (PDF)
Bioprocessing and Sterile Manufacturing
Advertisement
Articles in this issue
over 15 years ago
The Future of Downstream Processingover 15 years ago
Perspectives in MicroRNA Therapeuticsover 15 years ago
Bioprocessing Trends: Annual Surveyover 15 years ago
Regulation of Aseptic Processing in the 21st Centuryover 15 years ago
Technologies for Downstream Processing in Biologicsover 15 years ago
Peptide PEGylation: The Next Generationover 15 years ago
Strategies in Parenteral Drug ManufacturingAdvertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
3
First-in-Human Trial Speed: Why FDA Trails China
4
Formulation Strategies for Next-Generation Multiagonists
5